RFA+Highly-purified CTL vs. RFA Alone for Recurrent HCC

Launched by MING KUANG · Feb 8, 2016

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. age 18-75 years;
• • 2. recurrence of HCC 12 months after initial hepatectomy;
• • 3. no other treatment received except for the initial hepatectomy;
• • 4. single tumor≤5.0cm in diameter; or 2-3 lesions each≤3.0cm;
• • 5. lesions visible on ultrasound and with an acceptable and safe path between the lesion and the skin as shown on ultrasound;
• • 6. no severe coagulation disorders (prothrombin activity\<40% or a platelet count\<40,000/mm3);
• • 7. Eastern Co-operative Oncology Group performance(ECOG) status 0-1.
• Exclusion Criteria:
• • 1. Pregnant women, breastfeeding women or plan pregnancy for the future 2 years;
• • 2. The presence of vascular invasion or extrahepatic spread onimaging;
• • 3. Usage of strong immunosuppressive agents such as corticosteroids, cyclosporine A within six months or longer;
• • 4. HIV antibody or HCV antibody positive;
• • 5. Immunodeficiency diseases or autoimmune diseases (such as rheumatoid arthritis, Buerger's disease, multiple sclerosis and type 1 diabetes);
• • 6. Suffering with cancers (except skin cancer, prostate cancer or cervical carcinoma in situ) at the enrolling time or 5 years before;
• • 7. Suffering with other organ failure;
• • 8. Suffering with severe mental illness;
• • 9. Drug addiction (including alcohol) for 1 year before the enrolling time;
• • 10. Participate in other Clinical trials within three months prior to 3 months before the enrolling time;
• • 11. Other researchers believe that the patient is not fit for inclusion.

Trial Officials